Latest Updates
-
Struggling With Oily Skin This Summer? Simple Tips to Keep Shine Under Control -
Garlic Bread Recipe: The Cheesy Bakery Style Trick You Need -
Soha Ali Khan Swears By This ‘Gentle Game-Changer’ Lemon Drink for Gut Health: Full Recipe Inside -
World Health Day 2026: You’re Not As Healthy As You Think—Here’s Why -
One Pot Easy Lunch Recipe: Flavorful Veg Pulao -
Karan Aujla India Tour Controversy: Lucknow and Ludhiana Shows Cancelled—What Went Wrong? -
Kissing Disease Linked to 3x Higher Risk of Multiple Sclerosis: What You Should Know -
Feeling Drained in the Heat? 10 Healthy Drinks to Sip This Summer -
Happy Birthday Rashmika Mandanna: Steal Her White Looks For Easter 2026 Festive Parties And Celebrations -
Paneer Paratha Recipe: Crispy Outside, Soft Inside Perfection
Corbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said.

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed RBD protein subunit vaccine, Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
"The National Technical Advisory Group on Immunisation (NTAGI) will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated with Covishield or Covaxin," a source told PTI.
The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.
A separate HPV working group of the NTAGI had, on June 8, examined the vaccine's clinical trial data and usefulness for inclusion in the national immunisation programme, sources had said.
The recommendation of the Standing Technical Sub-Committee (STSC) of the NTAGI on reducing the gap between the second dose and the precaution dose of Covid vaccines from nine to six months may also be ratified at the meeting to be chaired by the Union health secretary. PTI PLB RC
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











